CRSP Insider Trading Activity and SEC Form 4 Filings
CRSP insider trading summary
Over the past 12 months, insiders at CRISPR Therapeutics AG (CRSP) reported 29 sales worth $17.7M by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $17.7M.
Latest CRSP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 19, 2026 | Samarth Kulkarni | Chief Executive Officer | Sell | $2.4M (47,837 @ $49.78) |
| Oct 14, 2026 | Samarth Kulkarni | Chief Executive Officer | Sell | $202K (4,098 @ $49.26) |
| Oct 14, 2026 | Simeon George | Insider | Sell | $720K (14,514 @ $49.63) |
| Oct 14, 2026 | James R. Kasinger | General Counsel and Secretary | Sell | $51K (1,040 @ $49.26) |
| Oct 6, 2026 | James R. Kasinger | General Counsel and Secretary | Sell | $119K (1,990 @ $60.04) |
| Sep 22, 2026 | James R. Kasinger | General Counsel and Secretary | Sell | $626K (10,400 @ $60.24) |
| Sep 17, 2026 | Ali Behbahani | Insider | Sell | $781K (13,679 @ $57.09) |
| Mar 23, 2026 | James R. Kasinger | General Counsel and Secretary | Sell | $149K (3,182 @ $46.78) |
| Mar 23, 2026 | Samarth Kulkarni | Chief Executive Officer | Sell | $469K (10,020 @ $46.78) |
| Mar 23, 2026 | Raju Prasad | Chief Financial Officer | Sell | $173K (3,708 @ $46.78) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.